Cinnamamide Derivatives Inhibit STAT3 for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer drugs face challenges such as side effects on normal cells, development of resistance, and low immune reactivity of cancer cells, particularly in the tumor microenvironment.
Innovation Solution
Development of novel cinnamamide derivatives that inhibit STAT3 activity, thereby inhibiting the growth of cancer cells and enhancing the activity of immune cells in the tumor microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If first-generation anticancer drugs are used to inhibit rapidly growing cancer cells, then cancer cell growth is inhibited, but side effects on normal cells occur
Solution Approach 1:
The patent develops targeted anticancer drugs that selectively inhibit STAT3 signaling in cancer cells while sparing normal cells. The compounds are designed to specifically bind to and inhibit STAT3 phosphorylation in the tumor microenvironment, achieving local selective action that differentiates between cancerous and normal tissues based on their distinct molecular characteristics
Solution Approach 2:
The patent introduces immune cells as intermediaries to mediate the anticancer effect. The cinnamamide derivatives enhance immune cell activity and promote immune-mediated destruction of cancer cells, rather than directly killing cancer cells. This intermediary mechanism allows normal cells to be spared while cancer cells are eliminated through the immune system
2Object-affected harmful factors
If second-generation targeted anticancer drugs are used to selectively attack cancer cells, then selectivity is improved, but drug resistance develops over time
Solution Approach 1:
The patent develops compounds that simultaneously perform multiple functions: inhibiting STAT3 signaling in cancer cells, modulating the tumor microenvironment, and enhancing immune cell activity. This multi-functional approach addresses multiple pathways involved in cancer progression and resistance, making it less likely for cancer cells to develop resistance through single pathway mutations
Solution Approach 2:
The patent utilizes the immune system as a feedback mechanism to continuously monitor and eliminate cancer cells. The enhanced immune cell activity creates an adaptive response that can recognize and adapt to evolving cancer cell characteristics, providing long-term control rather than static drug-target inhibition
3Object-affected harmful factors
If immune checkpoint inhibitors are used to activate T cells, then immune response is enhanced, but low immune reactivity of cancer cells limits effectiveness
Solution Approach 1:
The patent applies preliminary action by first modifying the tumor microenvironment and enhancing immune cell activity before cancer cells can suppress the immune response. The cinnamamide derivatives pre-condition the immune system and reduce immunosuppressive factors in the tumor microenvironment, making cancer cells more susceptible to subsequent immune attack
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to novel cinnamamide derivatives and use thereof in preventing or treating cancer.